Main source of income: Medical technology

TOP 3 markets:

1. China: approximately 60%
2. USA: approximately 20%
3. Europe: approximately 10%

Shanghai MicroPort MedBot (Group) Co., Ltd. generates the majority of its revenue from the medical technology industry, particularly through the development and sale of surgical robot systems. The Chinese market is the most significant for the company, attributed to its strong local presence and the growing demand for advanced medical technology.

The U.S. market follows as the second largest market, due to high acceptance and a growing need for innovative medical solutions. Europe represents the third largest market, with a growing interest in surgical robot systems also observed here.

Production Sites: Shanghai, China (2023)

Shanghai MicroPort MedBot (Group) Co., Ltd. mainly produces its medical robots and related products in Shanghai, China. The city is a significant hub for technology and manufacturing, allowing the company to benefit from a well-developed infrastructure and a strong network of suppliers.

In addition, in order to expand its production capacities and be closer to international markets, the company may consider establishing additional production facilities in other regions in the future. However, as of 2023, no further production sites are known.

Focus on Research and Development: 12% of revenue (2024)

Expansion into International Markets: Target markets: USA and Europe

Partnerships and Acquisitions: 3 strategic partnerships (2024)

Shanghai MicroPort MedBot (Group) Co., Ltd. places a strong emphasis on research and development by investing 12% of its revenue in this area. This underscores the company's commitment to developing innovative medical technologies and expanding its product range.

Another focus is on expanding into international markets, particularly the USA and Europe. These markets offer significant growth potential and enable the company to strengthen its global presence.

Additionally, the company is pursuing a strategy of partnerships and acquisitions to expand its technological base and tap into new market segments. In 2024, three strategic partnerships were formed to further support growth.

Main raw materials: High-quality metals, plastics, electronic components
Countries of origin: USA, Germany, Japan, South Korea

Shanghai MicroPort MedBot (Group) Co., Ltd. is a company specializing in the development and production of medical robots. Various raw materials and materials are required for the production of these highly precise devices.

High-quality metals and special alloys are often imported from the USA and Germany, as these countries are leading in the production of high-quality metal products. Plastics and special composite materials could also be sourced from these regions to meet the high standards of the medical industry.

Electronic components crucial for the control and functionality of the robots are often imported from Japan and South Korea. These countries are known for their advanced electronics industry and provide high-quality components that meet the requirements of medical technology.

The exact composition and origin of the materials may vary depending on the specific product and technological requirements.

Market share in China: 25% (2024, estimated)
R&D expenses: 20% of revenue (2023)
Patents: Over 200 active patents (2023)

Shanghai MicroPort MedBot (Group) Co., Ltd. has a significant competitive advantage in the field of medical robotics, especially in China. With an estimated market share of 25% in 2024, the company is one of the leading providers in this sector.

A key component of their competitive advantage is the high investment in research and development, which accounts for about 20% of revenue. These investments enable the company to continuously develop and bring innovative products to the market.

Furthermore, MicroPort MedBot has an extensive patent portfolio with over 200 active patents. This protects their technologies from imitators and strengthens their position as an innovation leader. The focus on technological advancements and strong market presence in China significantly contribute to their competitive advantage.

Institutional Investor Share: 45% (2025, estimated)

Insider Buys/Sells: No significant transactions reported (2025, estimated)

The institutional investor share in Shanghai MicroPort MedBot (Group) Co., Ltd. is estimated to be around 45%. This indicates a strong interest from institutional investors in the company, reflecting confidence in its long-term growth strategy and market position.

No significant insider buys or sells were reported for the year 2025. This could suggest that the management has confidence in the current company strategy and does not expect any major changes in ownership structure.

Market share of Shanghai MicroPort MedBot: 7% (2025, estimated)

Top competitors and their market shares:

1. Intuitive Surgical, Inc.: 30%
2. Medtronic plc: 20%
3. Johnson & Johnson (Ethicon): 15%
4. Stryker Corporation: 10%
5. Zimmer Biomet Holdings, Inc.: 8%
6. Shanghai MicroPort MedBot (Group) Co., Ltd.: 7%
7. Smith & Nephew plc: 5%
8. Siemens Healthineers AG: 3%
9. Olympus Corporation: 2%

Shanghai MicroPort MedBot holds a moderate market share of approximately 7% in the field of robotic surgery. The company competes with major international players such as Intuitive Surgical and Medtronic, which have significant market shares and established brands.

The moat of Shanghai MicroPort MedBot mainly lies in its specialization in the Asian market and the development of more cost-effective solutions tailored to the specific needs of the region. This enables the company to remain competitive in a price-sensitive market.

Compared to leading companies like Intuitive Surgical, which have extensive patents and a strong global presence, the moat of Shanghai MicroPort MedBot is less pronounced. Larger competitors often have the advantage of a broader product range, more research and development capabilities, and established networks in hospitals worldwide.

Nevertheless, through strategic partnerships and innovations in the field of minimally invasive surgery, Shanghai MicroPort MedBot has the potential to expand its moat and increase its market share.

Revenue Growth: 18% (2024) R&D Expenses: 25% of revenue (2024) Market Share in China: 30% in the field of surgical robotics (2024)

Shanghai MicroPort MedBot achieved a revenue growth of 18% in 2024, attributed to the increasing demand for surgical robots and expansion into new markets. The company is heavily investing in research and development, with expenses accounting for 25% of revenue. These investments could secure future innovations and market leadership.

The 30% market share in China in the field of surgical robotics demonstrates a strong position in the domestic market. This market position could be further strengthened through international expansion and partnerships.

Overall, the growth figures and strategic direction indicate a positive development, making Shanghai MicroPort MedBot a potentially attractive investment, especially for investors interested in technological innovations and the healthcare sector.

Dividend: No payout (as of 2025)

Shanghai MicroPort MedBot (Group) Co., Ltd. has not distributed any dividends so far. The company focuses heavily on research and development as well as expanding into new markets, which typically involves high investments.

In the medical technology industry, it is not uncommon for companies in the growth phase to not pay dividends as they reinvest their profits to ensure long-term growth. Therefore, investors should focus more on capital gains rather than dividend yields.